[1] Ott JJ,Stevens GA,Groeger J,et al.Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30:2212-2219.
[2] Lozano R,bNaghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.Lancet,2012,380:2095-2128.
[3] Izzedine H,Launay-Vacher V,Deray G. Renal tubular transporters and antiviral drugs: an update.AIDS,2005,19:455-462.
[4] Cheng Y,Vapurcuyan A,Shahidullah M,et al.Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs.Drug Metab Dispos,2012,40:617-624.
[5] Lee W,Glaeser H,Smith LH,et al.Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.J Biol Chem,2005,280:9610-9617.
[6] Urakami Y,Akazawa M,Saito H,et al. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol,2002,13:1703-1710.
[7] Xuan W,Lamhonwah AM,Librach C,et al.Characterization of organic cation/carnitine transporter family in human sperm.Biochem Biophys Res Commun,2003,306:121-128.
[8] Leung S,Bendayan R.Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs.Can J Physiol Pharmacol,1999,77:625-630.
[9] Huls M,Brown CD,Windass AS,et al.The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.Kidney Int, 2008,73:220-225.
[10] Fontana RJ.Side effects of long-term oral antiviral therapy for hepatitis B.Hepatology,2009,49:S185-195.
[11] Xu Q,Wang C,Meng Q,et al.OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485.Eur J Pharm Sci,2013,48:650-657
[12] Uteng M, Mahl A, Beckmann N,et al. Editor’s highlight: comparative renal safety assessment of the hepatitis Bdrugs, adefovir, tenofovir, telbivudine and entecavir in rats.Toxicol Sci,2017,155:283-297.
[13] Yang X,Ma Z,Zhou S,et al.Multiple drug transporters are involved in renal secretion of entecavir. Antimicrob Agents Chemother,2016,60:6260-6270.
[14] Tien C,Xu JJ,Chan LS,et al.Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci,2015,60:566-572.
[15] Cihlar T,Birkus G,Greenwalt DE,et al.Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.Antiviral Res,2002,54:37-45
[16] Kohler JJ,Hosseini SH,Hoying-Brandt A,et al.Tenofovir renal toxicity targets mitochondria of renal proximal tubules.Lab Invest,2009,89:513-519.
[17] Reid G,Wielinga P,Zelcer N,et al.Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.Mol Pharmacol,2003,63:1094-1103.
[18] Perazella MA.Tenofovir-induced kidney disease:an acquired renal tubular mitochondriopathy. Kidney Int,2010,78:1060-1063.
[19] Wu X,Cai S,Li Z,et al.Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis.Virol J,2016,13:64.
[20] Zhou XJ,Marbury TC,Alcorn HW, et al.Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.Antimicrob Agents Chemother,2006,50:1721-1726.
[21] Hagos Y,Wolff NA.Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.Toxins (Basel),2010,2:2055-2082.
[22] Wong CC,Botting NP,Orfila C,et al.Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6).Biochem Pharmacol,2011,81:942-949.
[23] Wang L,Sweet DH.Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.AAPS J,2013,15:53-69.
[24] Cha SH,Sekine T,Fukushima JI,et al.Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.Mol Pharmacol,2001,59:1277-1286.
[25] Wijnholds J,Mol CA,van Deemter L,et al.Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.Proc Natl Acad Sci USA,2000,97:7476-7481.
[26] Nakatani-Freshwater T,Babayeva M,Dontabhaktuni A,et al.Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney.Pharmacol Exp Ther,2006,319:941-947.
[27] Moore KH,Yuen GJ,Raasch RH,et al.Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.Clin Pharmacol Ther,1996,59:550-558.
[28] Minuesa G,Volk C,Molina-Arcas M,et al.Transport of lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.J Pharmacol Exp Ther,2009,329:252-261.
[29] Wada S,Tsuda M,Sekine T,et al.Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.J Pharmacol Exp Ther,2000,294:844-849. |
